ASH 2018 | Nivolumab with ibrutinib for Richter’s transformation
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Outcomes for chronic lymphocytic leukemia (CLL) patients with Richter’s transformation (RT) are poor, with a median survival of less than 1 year with chemoimmunotherapy. Here, Nitin Jain, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase II clinical trial investigating the combination of nivolumab, an anti-PD1 monoclonal antibody, with ibrutinib in patients with relapsed/refractory CLL or RT (NCT02420912). Dr Jain discusses the safety and efficacy data, revealing the combination of nivolumab and ibrutinib to have clinical activity. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up
Targeting T-cell malignancies with CRISPR/Cas9 gene edited universal CAR-T
Advances in the field of HSCT
Clinical practice recommendation on HSCT for AML with FLT3-internal tandem duplication
Reduced-intensity conditioning regimens in ALL patients undergoing allo-HSCT
Germline predisposition to AML
More from Nitin Jain